Patents Assigned to GW Pharma Limited
  • Publication number: 20210221587
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: October 1, 2020
    Publication date: July 22, 2021
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20210128657
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Application
    Filed: June 18, 2020
    Publication date: May 6, 2021
    Applicant: GW Pharma Limited
    Inventors: BRIAN ANTHONY WHITTLE, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
  • Publication number: 20210069333
    Abstract: The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
    Type: Application
    Filed: November 23, 2020
    Publication date: March 11, 2021
    Applicant: GW Pharma Limited
    Inventors: Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES
  • Publication number: 20210059959
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: April 10, 2020
    Publication date: March 4, 2021
    Applicant: GW Pharma Limited
    Inventors: Philip ROBSON, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Patent number: 10807777
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 20, 2020
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 10799467
    Abstract: This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy. The invention further relates to the use of the phytocannabinoid CBDV in combination with standard anti-epileptic drugs (SAEDs). Preferably the SAED is one of ethosuximide, valproate or phenobarbital.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: October 13, 2020
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co. Limited
    Inventors: Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
  • Publication number: 20200306328
    Abstract: The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to a medicament. It also relates to a BDS of given purity, for use in pharmaceutical formulations. In particular it relates to BDS comprising cannabinoids obtained by extraction from cannabis.
    Type: Application
    Filed: October 30, 2019
    Publication date: October 1, 2020
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Colin A. Hill, Ian R. Flockhart, David Victor Downs, Peter Gibson, Gary William Wheatley
  • Patent number: 10758514
    Abstract: The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: September 1, 2020
    Assignee: GW Pharma Limited
    Inventors: Wai Liu, Katherine Scott, Angus Dalgleish, Marnie Duncan, Colin Stott
  • Patent number: 10729665
    Abstract: This invention relates to a pharmaceutical composition comprising or consisting essentially of the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD). The composition is particularly safe and efficacious for use in the treatment of neurological conditions, characterized by hyper-excitability of the central nervous system, convulsions or seizures such as occur in epilepsy. Preferably the CBDV and the CBD are present with at least one non-cannabinoid component of cannabis such as one or more terpenes or a terpene fraction. More particularly the composition further comprises one or more cannabichromene type compounds. Particularly cannabichromene propyl variant (CBCV) and/or cannabichromene (CBC).
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 4, 2020
    Assignees: GW Pharma Limited, Otsuka Pharmaceutical Co., Limited
    Inventors: Benjamin Whalley, Claire Williams, Gary Stephens, Thomas Hill
  • Publication number: 20200206184
    Abstract: The invention relates to the use of a combination of cannabinoids for the treatment of pain, inflammation and/or disease modification in arthritis. Preferably the cannabinoids are selected from cannabidiol (CBD) or cannabidivarin (CBDV) and delta-9-tetrahydrocannabinol (THC) or tetrahydrocannabinovarin (THCV). More preferably the cannabinoids are in a predefined ratio by weight of less than or equal to 19:1 of CBD or CBDV to THC or THCV.
    Type: Application
    Filed: September 6, 2019
    Publication date: July 2, 2020
    Applicant: GW Pharma Limited
    Inventors: PHILIP ROBSON, Geoffrey Guy
  • Publication number: 20200206151
    Abstract: Cannabinoids, in particular CBD and CBDA and their acid derivatives are provided for use as an active pharmaceutical substance in the treatment of nausea, vomiting, emesis, motion sickness. In particular extracts of cannabis plants are presented which are rich in these substances and suitable for pharmaceutical use.
    Type: Application
    Filed: August 6, 2019
    Publication date: July 2, 2020
    Applicant: GW Pharma Limited
    Inventors: BRIAN ANTHONY WHITTLE, Farideh Afshin Javid
  • Patent number: 10653641
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20200138771
    Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multifonne (GBM).
    Type: Application
    Filed: June 7, 2019
    Publication date: May 7, 2020
    Applicant: GW Pharma Limited
    Inventors: Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES, Fatima RODRIGUEZ
  • Publication number: 20200102131
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: December 3, 2019
    Publication date: April 2, 2020
    Applicant: GW Pharma Limited
    Inventor: BRIAN ANTHONY WHITTLE
  • Patent number: 10538373
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 21, 2020
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20190322427
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: January 11, 2019
    Publication date: October 24, 2019
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20190270563
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: May 21, 2019
    Publication date: September 5, 2019
    Applicant: GW Pharma Limited
    Inventor: BRIAN ANTHONY WHITTLE
  • Publication number: 20190255011
    Abstract: The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 22, 2019
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony WHITTLE, Daniela PAROLARO
  • Publication number: 20190224140
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 25, 2019
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa
  • Patent number: 10258580
    Abstract: The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 16, 2019
    Assignee: GW Pharma Limited
    Inventors: Teresa Iuvone, Vincenzo Di Marzo, Geoffrey Guy, Stephen Wright, Colin Stott